

22<sup>nd</sup> May 2023

**VENTURE LIFE GROUP PLC**  
("Venture Life", "VLG" or the "Company")

**AGM statement**

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, will hold its Annual General Meeting ("**AGM**") at 10:00am this morning. At the meeting, the Group's Chair, Paul McGreevy will make the following statement:

"On behalf of the Board, I would like to take the opportunity to thank Venture Life's employees for their continued commitment and support. The business is in good health, consumer demand for our brands continues to grow and our order book remains strong. The recent acquisition of HL Healthcare Limited ("HLH") has been fully integrated and is performing as expected.

"In line with the comments made at the FY 2022 results at the beginning of April, we remain cautiously optimistic about the outlook for the year ahead and our ability to deliver full year performance in line with market expectations. Further commentary on our first half trading will be provided in our trading update in July 2023."

**For further information, please contact:**

**Venture Life Group PLC**

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

**Cenkos Securities plc (Nomad and Joint Broker)**

+44 (0) 20 7397 8900

Stephen Keys / Camilla Hume (Corporate Finance)

Michael Johnson (Sales)

**Singer Capital Markets (Joint Broker)**

Shaun Dobson / Alaina Wong (Corporate Finance)

+44 (0) 20 74963000

Jonathan Dighe (Sales)

**About Venture Life ([www.venture-life.com](http://www.venture-life.com))**

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGMUASBROOUVUAR